ARTICLE | Product Development

Not dead yet

How to interpret CTAD data for Lilly, Biogen anti-amyloid mAbs in AD

December 17, 2016 3:37 AM UTC

The amyloid hypothesis may not be dead, but positive Phase Ib data for Biogen Inc.’s aducanumab notwithstanding, the preponderance of evidence still suggests that attacking plaques is unlikely to be an effective intervention for Alzheimer’s disease.

The near-simultaneous report that Eli Lilly and Co.’s solanezumab did not clear plaques in the failed EXPEDITION 3 trial and that aducanumab did - while also slowing cognitive decline - sent Biogen’s shares up and spawned headlines suggesting a breakthrough had been reached...

BCIQ Company Profiles

Biogen Inc.

Eli Lilly and Co.

BCIQ Target Profiles

Beta amyloid